Epithelioid Hemangioendothelioma — Trials

Epithelioid Hemangioendothelioma — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 4
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: BridGene Biosciences Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03331250	Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)	completed	Phase 2	13	Massachusetts General HospitalOTHER	1	Aug 28, 2026	clinicaltrials
NCT06239272	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)	recruiting	Phase 1 / Phase 2	139	St. Jude Children's Research HospitalOTHER	1	Aug 3, 2026